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In Norway, the standardized incidence of testicular cancer has
increased from 2.7 per 100 000 in 1955 to 8.5 per 100 000 in 1992,
with little difference between seminoma and non-seminoma
(Wanderaas et al, 1995). The mean age of seminoma and non-
seminoma patients at the time of diagnosis is 40 and 32 years
respectively. When confronted with such a diagnosis, most of
these young men ask their responsible physician about their
chances of having children after treatment. Though many mono-
institutional studies have demonstrated that long-term sperm cell
production and ejaculation are preserved in the majority of
patients treated during the last decade (Petersen et al, 1998;
Jacobsen et al, 1999), population-based studies on post-treatment
fertility are rare.
From clinical praxis it has been suspected for a long time that
there are links between sub- or infertility and the development of
testicular cancer (Giwermann and Petersen, 1998). In 1994, the
United Kingdom Testicular Cancer Study Group described a
significant association between low fertility or sterility and the risk
of being diagnosed with testicular cancer. Møller and Skakkebæk
(1999) demonstrated that paternity by itself and increasing parity
were associated with a lower risk of testicular cancer.
The objective of this study was to check whether Norwegian
testicular cancer patients had fewer children before diagnosis than
men of the same age without this disease and, more importantly,
whether their fertility after diagnosis differed from that of others.
Stage and histology, and thereby largely the treatment modality
(radiotherapy, chemotherapy, retroperitoneal surgery), were taken
into account. Also, the changes over time were assessed.
MATERIALS AND METHODS
The analysis was based on individual sociodemographic life
histories up to the end of 1991 for all men with a Norwegian
personal identification number (given to everyone who has lived
in Norway for some time after 1960) who are born after 1935.
These ‘life histories’ were extracted from the Norwegian
Population Register and the Population Censuses of 1960, 1970
and 1980, and included information about date of death and
emigration, date of birth for all children the man fathered up to
1991, marital status, education and various other socioeconomic
characteristics at the time of the censuses. The data were based on
a social definition of parenthood, i.e. the fathers were linked with
their social rather than biological offspring.
These life histories were matched with data from the Norwegian
Cancer Registry, which from 1953 has received information on all
cancer cases in the country. This compulsory reporting system is
based on pathology and cytology reports, clinical records and
death certificates, and provides information about site, basis for
the diagnosis, histological grade and type, and the stage of the
disease at the time of diagnosis. The matching of the data was
approved by the Norwegian Data Inspectorate.
The multiplicative Poisson regression model
(1) f = exp(bx) exp(cy)
was estimated for the birth intensity f. x is a vector of sociodemo-
graphic covariates age, period, parity, duration since previous
birth, marital status and educational level. These covariates are all
categorical and time-varying. A level for each covariate is defined
for each month during the follow-up period, and refers to the situ-
ation at that time (age, period, parity, duration) or that in the last
previous census (education, marital status).
The variable y is a categorical time-varying disease indicator
with one level up to the diagnosis of a testicular cancer, if any, and
3–5 levels afterwards, defined as a combination of stage and
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ized’ (non-metastatic, stage I), ‘regional’ (spread to regional
lymph nodes, stage II), haematogeneous ‘distant’ spread (i.e. to
parenchymatous organs or to non-regional lymph nodes, stage III)
or unknown (only 1%). Because of the small size of the latter cate-
gory, it is combined with localized. The effect vectors are b and c.
The men were followed from age 17 and censored at the time of
emigration, death, or the end of 1991. In principle, all parity tran-
sitions can be considered in such an analysis (up to 18, which is
the highest parity reached in these data), but for practical reasons a
limit was set. It was decided to censor at the birth of the third 
child, because few Norwegian men have more than three 
children (Kravdal, 1994).
For cancer patients, censoring was done at the time of the first
birth after diagnosis. This is because fertility among those who
have already proved their fertility by having one child after diag-
nosis is much less interesting. In other words, c is a measure of
how the chance of having child number n + 1 differs between two
groups of men who currently have had n children, the same dura-
tion since last birth, the same age and also the same other observed
sociodemographic characteristics. One group comprises those who
had a testicular cancer and had all their children before diagnosis;
the other group comprised those without such a diagnosis.
Separate models were estimated for seminoma and non-
seminoma, and for patients diagnosed before 1980 and thereafter.
This cut-off point was chosen because of the important treatment
changes initiated at that time (Fosså et al, 1991). The following is
a brief summary of these changes.
Up to 1980, all patients with stage I disease were treated by
abdominal radiotherapy (target dose 40–50 Gy). Stage II patients
received the same radiotherapy in addition to mediastinal irradia-
tion. Patients with distant metastases or with recurrent malignancy
were treated by available chemotherapy (without cisplatin).
From 1980, non-seminoma stage I patients underwent retroperi-
toneal lymph node dissection (RPLND). After 1988, such patients
were included in a surveillance policy. Metastatic or recurrent
patients were given cisplatin-based combination chemotherapy
followed by surgery. In stage I seminoma patients, the target dose to
the para-aortic lymph nodes was reduced from 40 Gy to 30 Gy.
Metastatic seminoma was treated with cisplatin-based chemotherapy
and small-field irradiation.
Five-year relative survival rates increased from 61% in the late
1960s to 93% in the late 1980s (Cancer Registry, 1993).
As a supplementary and simple description of the impact of
testicular cancer on fertility, the probabilities of having had a first
child were calculated for different ages for persons who were
childless at, say, age 20. If A is the integral of the first-birth rates
from age 20 up to the age in focus, such a probability P (also
denoted as a ‘partial’ probability, because it is based on birth rates
exclusively, thus disregarding the chances of not surviving up to
that age) is given by
(2) P = 1 – exp(–A)
Constant birth rates are assumed for 1-year intervals, and are esti-
mated by dividing the number of births in each interval by the
corresponding exposure time.
In addition, the multiplicative Poisson regression model
(3) i = exp(dz)
was estimated for the cancer incidence i. z is a vector of sociode-
mographic covariates age, period, marital status, educational level
(defined as in the fertility model) and parity. Parity was defined for
each month of follow-up and referred to the total number of chil-
dren the man had fathered up to that time. In other words, it was
estimated how the risk of being diagnosed with testicular cancer at
a given age was related to parity at that age, net of differences in
period, education and marital status. The men were followed from
age 17 up to time of emigration, death or the end of 1991. This
method was also used with these data in several studies of other
cancer types (Kravdal, 1995; Harvei and Kravdal, 1997).
The models were estimated in the AMFIT module in the
EPICURE program system (Preston et al, 1993). A self-made
program (in the PASCAL language), operating on the individual-
level register and census data, was used to compute the multi-
dimensional tables of events (number of births or cancer cases)
and exposures that were fed into AMFIT.
RESULTS
During the period under study, seminoma and non-seminoma
patients fathered 171 and 250 children, respectively, within 10
years after diagnosis (Table 1). In comparison, there were 1.3
million births among other men (not shown).
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Table 1 Fertility rates for Norwegian men with a testicular cancer diagnosis fewer than 10 years previously, relative to men without such a diagnosis (with 95%
confidence intervals)a
Non-seminoma Seminoma
Estimates n Estimates n
Men without testicular cancerb 1.0 1.0
Men with testicularcancer 
diagnosed fewer than 10 
years previously
Local 0.78c (0.67–0.91) 172 0.69c (0.59–0.81) 147
Regional 0.45c (0.34–0.60) 48 0.14c (0.03–0.55) 19
Distant 0.33c (0.23–0.47) 30 0.35c (0.18–0.67) 5
aOnly the effects of the disease variable are shown in the Table, but also age (15 levels), period (4 levels), parity (0, 1, or 2), duration since last previous birth 
(7 levels), education (4 levels) and marital status (4 levels) were included in the model. It was censored 10 years after diagnosis, if any. bReference category.
cSignificantly different from 1 at the 5% level. n, number of births among men in this category.Fertility in testicular cancer patients 739
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Men with testicular cancer age 17–20
Figure 1 (A) Probabilities of having had a first child, by age, among Norwegian men with or without a testicular cancer diagnosis who were childless at age 20.
(B) Probabilities of having had a first child, by age, among Norwegian men with or without a testicular cancer diagnosis who were childless at age 25
Table 2 Fertility rates for Norwegian men with a testicular cancer diagnosis, relative to men without such a diagnosis (with 95% confidence intervals)a
Before 1980 After 1980
Estimates n Estimates n
Non-seminoma
Men without tesitcular cancerb 1.0 1.0
Men with testicular cancer diagnosed fewer
than 5 years previously
Local 0.72c (0.56–0.94) 58 0.85 (0.67–1.06) 78
Regional/distant 0.25c (0.13–0.48) 9 0.49c (0.36–0.64) 55
Men with testicular cancer diagnosed
5–10 years previously
Local 1.08 (0.64–1.59) 17 0.57c (0.37–0.90) 19
Regional/distant 0.45 (0.11–1.82) 2 0.26c (0.15–0.46) 12
Men with testicular cancer diagnosed
more than 10 years previously
Local
Regional/distant 0.65 (0.37–1.18) 11 0.71c (0.53–0.97) 41
Seminoma
Men without testcular cancerb 1.0 1.0
Men with testicular cancer diagnosed fewer
than 5 years previously
Local 0.77 (0.58–1.02) 49 0.61c (0.49–0.77) 72
Regional/distant 0.41c (0.17–0.99) 5 0.49c (0.29–0.85) 13
Men with testicular cancer diagnosed
5–10 years previously
Local 0.63 (0.24–1.41) 6 0.75 (0.48–1.16) 20
Regional/distant 0.40 (0.06–2.86) 1 0.56 (0.23–1.35) 5
Men with testicular cancer diagnosed
more than 10 years previously
Local
Regional/distant 0.47 (0.15–1.46) 3 0.86 (0.55–1.34) 19
aOnly the effects of the disease variable are shown in the Table, but also age, period, parity, duration since last previous birth, education and marital status were
included in the model. The categories are as described in notea to Table 1. bReference category. cSignificantly different from 1 at the 5% level. n, number of
births among men in this category.In the regression estimates presented, only the relation between
fertility and the disease variable is diplayed (Table 1) (controls for
education and marital status were included, but were not impor-
tant). Having a localized cancer reduced fertility by about 30%
compared to the normal population, while a stronger reduction was
seen among men whose cancer had spread at the time of diagnosis.
These estimates are for the entire 10-year period after diagnosis.
The deviation from normal fertility was slightly more pronounced
during the first few years after diagnosis (not shown).
As a simple illustration, the probabilities of having had a first child
within different ages are plotted in Figure 1 for men born 1945–1965.
In Figure 1A, probabilities are shown for two groups of men who
were still childless at age 20. One group includes about 100 men who
were diagnosed with testicular cancer at age 17–20 (regardless of
stage and histology), and the other group includes all other men. In
the latter group, 76% had a child when they were 41 years old,
whereas the corresponding proportion among the testicular cancer
patients was only 42%. Similar probabilities for two groups of men
who were still childless at age 25 are plotted in Figure 1B. One group
includes about 250 men with a testicular cancer diagnosis at age
17–25, and the other group includes all other men.
Separate regression models were estimated for periods before
and after 1980 (Table 2). For non-seminoma, there were quite
strong indications of an increasing relative fertility over time when
it was focused on men who had been diagnosed with metastasis
less than 5 years previously. Before 1980, men in this situation
only had nine children, whereas the corresponding number for the
later period was 55. These differences reflect, of course, both
fertility rates and the number of men under exposure for births,
which in turn was determined by testicular cancer incidence as
well as survival. The fertility rates were estimated to have
doubled, from one-quarter of the level among other men before
1980, to one-half in the later period. The confidence intervals
barely overlapped. With respect to fertility 5–10 years after diag-
nosis, there were indications, albeit weaker, of an opposite trend
over time. For seminoma, there were very modest differences in
relative fertility between the periods before and after 1980.
The risk of developing seminoma depended significantly on
parity. For example, the risk for a man with three children was
40% lower than that for a childless, but otherwise similar, man.
The risk for a four-child father was not significantly reduced, but
the group was quite small. When pooled together, a relative risk of
0.67, significantly different from 1, appeared for those with three
or more children (Table 3). On the other hand, there was no associ-
ation between parity and the non-seminoma incidence.
DISCUSSION
The birth rates in this study reflect almost exclusively the in vivo
biological fertility. Adoptions are very rare in Norway, and assisted
fertilization also counts very little. Furthermore, the few children
born fewer than 9 months after their father’s diagnosis of testicular
cancer are considered as ‘post-treatment’, although their conceptions
most probably had taken place prior to the diagnosis and treatment.
Our strategy of censoring at the time of a first birth after diag-
nosis was not critical for the results. Also, those who already had a
child after diagnosis, and thus signal an ability to conceive,
displayed a subsequent fertility lower than that of men at the same
parity level without the testicular cancer diagnosis. This deficit
was similar to that for the first birth after diagnosis.
Testicular cancer was found to be associated with relatively low
fertility before diagnosis. Seminoma patients, but not those with
non-seminoma, had significantly fewer children at the time of
diagnosis than men with otherwise similar socio-demographic
characteristics. We thus confirm the results of the two former
comparable epidemiological studies (United Kingdom Testicular
Cancer Study Group, 1994; Möller and Shakkebæk, 1999). The
most plausible explanation for the relationship between (prediag-
nostic) subfertility and the seminoma incidence is that some types
of primary hypogonadism and seminoma may share some aetio-
logical factors during early embryonal life, leading to disturbed
differentiation of primordial cells – the cells from which the male
gonads develop. This disturbance may be expressed as infecun-
dity, reduced spermatogenesis, and may even contribute to the
development of testicular cancer, in particular seminoma, affecting
one or both of the testicles. The fact that parity effects are less
pronounced in non-seminoma patients could perhaps be partly due
to their generally lower age. At a relatively low age, low parity is
more a signal of choice, while it is more likely to indicate
physiological limitations at a higher age.
A clinical implication of this result is that especially the child-
less older seminoma patients should undergo treatment which is as
fertility-saving as possible in order to allow a maximum recovery
of the spermatogenesis. These arguments strongly favour the
application of a wait-and-see policy in patients who want to father
a child after diagnosis (Warde et al, 1993).
In addition to a low prediagnostic fertility for seminoma
patients, birth rates were low also after a testicular cancer diag-
nosis compared to those of other men at the same age and parity in
the same period. Among men with localized cancers, of either
histological type, the birth rates after diagnosis were about 
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Table 3 Effects of parity on the risk of being diagnosed with testicular cancer (with 95% confidence intervals)a
Non-seminoma Seminoma
Estimates n Estimates n
0 childb 1.00 596 1.00 379
1 child 1.03 (0.87–1.21) 213 0.76c (0.63–0.92) 163
2 children 0.97 (0.81–1.16) 233 0.78c (0.66–0.92) 289
3 children 0.83 (0.64–1.08) 76 0.60c (0.47–0.75) 104
4 or more children 1.10 (0.75–1.62) 31 0.80 (0.58–1.09) 50
aOnly the effects of parity are shown in the Table, but also age, education are marital status were included in the model. The
categories are as described in note a to Table 1. bReference category. cSignificantly different from 1 at the 5% level. n, number
of diagnoses among men in this category.one-quarter lower than in the remaining population, while the gap
was more than twice as large in cases of metastasized cancers.
There are several possible reasons for this lowered fertility after
diagnosis and treatment. One reason, which is relevant only for the
seminoma patients, is a continuing influence of an inherent sub- or
infecundity that also existed before diagnosis. Another reason is a
reduced desire for more children after an exhausting treatment for
a life-threatening malignancy. A perceived risk of malformations
of the offspring due to prior cytotoxic therapy of the father may
also contribute to weaken fertility desires and may lead not only to
postponement but also rejection of further childbearing. Any such
voluntary postponement of post-treatment fatherhood is, of course,
of greater significance for the generally older seminoma patients
(and their partners) than for those with non-seminoma.
Possibly the most important reason for the low post-diagnostic
fertility among testicular cancer patients is the treatment. The 
use of abdomino-pelvic radiotherapy and cytostatics leads to
decreased spermatogenesis, which, depending on the type of treat-
ment and cumulative doses and the patient’s age, may or may not
recover. Secondly, traditional RPLND, performed in many non-
seminoma patients before 1985 with the complete resection of
sympathetic nerve fibres, leads to ‘dry ejaculation’ and thus to
infecundity. The change of treatment modalities after 1980 is
expected to have reduced the risk of treatment-induced infecundity
for patients treated after 1980 (Petersen et al, 1998; Jacobsen et al,
1999). The Registry data support the expectations, and demon-
strate that this effect is most pronounced in metastatic non-semi-
noma patients, though the picture is not entirely consistent. When
the focus is on the first 5 years after diagnosis, there are indications
of improvement in fertility for the observation period 1980–1991.
On the other hand, there are also weak indications of a gradually
larger fertility deficit during recent years among men diagnosed
with testicular cancer 5–10 years previously. This might be
explained by a changing force of selection: with current standard
chemotherapy, spermatogenesis recovers after 2–3 years, whereas
the recovery took place later, if ever, in the 1960s and 1970s. The
patients treated after 1980 who had still not had a child 5 years
after diagnosis, in spite of the improved therapy, may to a much
larger extent than before comprise a group of persons with treat-
ment-independent infecundity problems or weak fertility desires.
The favourable time trend will probably continue among non-
seminoma patients as a result of the surveillance policy and nerve-
sparing RPLND since 1989. In seminoma patients, improvement
of fertility will presumably be less pronounced, as long as changes
in the treatment remain more limited.
In summary, this study shows, first, that the fertility rates among
Norwegian testicular cancer patients born after 1935 and treated
before 1991 decreased by roughly 30% when compared with the
normal population. Secondly, there are quite strong indications
that the introduction of cisplatin-based chemotherapy and limited
or nerve-sparing RPLND in the 1980s made it possible for more
non-seminoma patients to have (another) child after diagnosis, or
at least to have a child earlier. Thirdly, the risk of being diagnosed
with seminoma is reduced with increasing parity. This suggests
that the relatively low fertility after diagnosis may be partly due to
the continuing influence of sub- or infecundity problems that also
had a bearing on the development of the disease. Consequently,
introduction of a wait-and-see policy for childless patients with
stage I seminoma may be advantageous in an attempt to preserve
pre-existing (though low) fertility as much as possible.
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